SI-BONE, Inc. SIBN Weighted Average Exercise Price of Exercisable Options

Weighted Average Exercise Price of Exercisable Options at other companies

Globus MedicalGMED

——

BioventusBVS

——

Other financials

Income statement

See full

Revenue$52.6M+11.2%

Gross profit$41.9M+11.3%

Operating income-$5.1M+31.9%

Net income-$4.3M+33.8%

EPS (diluted)-$0.10+33.3%

Balance sheet

See full

Cash & equivalents$33.5M-18.6%

Total debt$42.9M+15.6%

Total equity$178.9M+7.0%

Total assets$242.7M+6.8%

Cash flow

See full

Operating cash flow-$2.4M+51.9%

CapEx$1.1M-48.0%

Free cash flow-$3.4M+50.8%

Valuation

See full

Market cap$743.29M+6.4%

Enterprise value$752.71M+8.4%

P/S3.6×-0.4×

Profitability

See full

Gross margin79.6%+0.3pp

Operating margin-9.7%-3.0pp

Net margin-8.1%-2.6pp

FCF margin-2.9%-1.2pp

Returns & leverage

See full

Return on equity-9.6%-2.7pp

Debt / equity0.2×0.0×

Current ratio10×+1.5×

Where this comes from

Reported directly by SI-BONE, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice.

The official record: SI-BONE, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about SI-BONE, Inc.'s weighted average exercise price of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SI-BONE, Inc.'s weighted average exercise price of exercisable options?: SI-BONE, Inc. (SIBN) reported weighted average exercise price of exercisable options of $12.07 in Q1 2026.
How has SI-BONE, Inc.'s weighted average exercise price of exercisable options changed year-over-year?: SI-BONE, Inc.'s weighted average exercise price of exercisable options increased by 8.7% year-over-year, from $11.10 to $12.07.